Dr. Preeti Mehta is an experienced patent agent with a practice focused on US and international patent preparation and prosecution, patentability analyses, freedom-to-operate assessments, patent landscape analyses, licensing support and patent portfolio management for clients in the life sciences industry. She also has experience supporting Hatch-Waxman invalidity and non-infringement analyses.
Preeti has experience drafting and prosecuting patent applications across a broad range of sectors, including cell and gene therapies, immunology, oncology, diagnostics, microbiome technologies, pharmaceuticals and food sciences. Representative examples of technologies include gene editing, viral vectors, nucleic acid therapeutics, antibody therapeutics, cell therapies, companion diagnostics, organoids and microbiome-based products.
Prior to beginning her intellectual property career, Preeti spent more than 20 years as a molecular biologist and researcher. Her scientific experience includes neuroscience, microbiology, biochemistry, genomics, genetic engineering, bioinformatics and immunology. She held research appointments at the University of Texas at Austin, Stony Brook University and the University of Pittsburgh.
Representative experience
Therapeutics
-
Cell therapy technologies, including CAR-T, CAR-NK, TCR-T, engineered macrophages, engineered stem cells, iPSC-derived cell products, hematopoietic cell therapies, tumor-infiltrating lymphocytes (TILs) and regulatory T cells (Tregs), spanning cell collection and isolation, cellular engineering, receptor construct design, ex vivo modification, cell expansion and differentiation, manufacturing, formulation and cryopreservation and safety switch technologies.
-
Gene therapy technologies, including adeno-associated virus (AAV), lentiviral and adenoviral vector systems, lipid nanoparticle (LNP) delivery platforms and nucleic acid therapeutics, covering vector engineering, expression constructs, targeting strategies and production and formulation methods.
-
Genome engineering technologies, including CRISPR/Cas systems, zinc finger nucleases (ZFNs), TALENs, base editing, prime editing and guide RNA technologies, including editing constructs, delivery systems, target site selection and ex vivo and in vivo editing approaches.
-
Antibody and protein therapeutics, including monoclonal, humanized and fully human antibodies, bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), antibody fragments (for example, Fab, scFv and VHH/single-domain formats), variable and constant region engineering (including Fc modifications), antibody-based fusion proteins, chimeric antigen receptors (CARs) and T-cell receptor (TCR) constructs, as well as receptors, ligands, cytokines, growth factors, hormones and antigen/neoantigen vaccine technologies (including mRNA, recombinant, subunit and conjugate vaccines).
-
Microbiome-based therapeutics, including live biotherapeutic products (LBPs), engineered microbial therapeutics, microbial consortia, probiotic formulations and phage- and microbial metabolite-based therapies, together with microbiome-modulating agents and fecal microbiota transplantation (FMT) approaches for indications including inflammatory bowel disease, Crohn's disease, ulcerative colitis and other gastrointestinal, infectious, oncological and metabolic conditions.
Diagnostics
-
Companion diagnostics and precision medicine technologies for patient stratification, treatment selection, response prediction, resistance monitoring and therapeutic efficacy assessment, involving genomic, transcriptomic, proteomic, immunological, cellular and microbiome-based biomarkers, sequencing- and PCR-based methods, liquid biopsy technologies and biomarker panels.
-
Molecular diagnostic technologies involving genomic DNA, cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), mRNA and other coding and non-coding RNA biomarkers and epigenetic markers (including DNA methylation signatures), using sequencing-based methods, PCR- and qPCR-based assays, next-generation sequencing (NGS), multiplex detection and liquid biopsy platforms.
-
Protein-, cell- and biomarker-based diagnostic technologies, including immunoassays, flow cytometry, immunohistochemistry (IHC), mass spectrometry-based detection, ELISA-based platforms and multi-omics approaches, as well as diagnostics based on circulating tumor cells (CTCs), immune cells and other cellular populations involving single-cell analysis and cell sorting.
Research instruments/tools
-
Organoid technologies, including patient-derived organoids, stem-cell- and iPSC-derived organoids, tumor organoids and engineered organoid systems, covering induction and differentiation protocols, three-dimensional culture systems, biomaterials and scaffolds, co-culture systems, disease modeling and drug discovery platforms.
-
Genomics, transcriptomics and multi-omics technologies, including next-generation sequencing, gene expression profiling and biomarker discovery.
-
Cellular engineering, cell culture, cell expansion, differentiation and ex vivo cell modification technologies supporting cell therapy and organoid development.
Food science and biomass
-
Microbial and animal-derived biomass technologies, including engineered microbial strains (for example, yeast, fungi and algae) and animal cell culture-based materials.
-
Food science innovations, dietary supplements, nutritional products and functional food technologies.
-
Consumer health, personal care and cosmetic technologies, including cosmetic and skin care formulations, bio-derived and naturally sourced functional ingredients and surfactant technologies for cleansing, emulsification, conditioning and product stability.
Education
PhD, Madurai Kamaraj University, 2003
MS, Madurai Kamaraj University, 1997
BS, Delhi University, 1995
Admissions
- US Patent and Trademark Agent
Publications
- Co-author, “Excitatory cholecystokinin neurons of the midbrain integrate diverse temporal responses and drive auditory thalamic subdomains,” Proceedings of the National Academy of Sciences 2021 118 (10):e2007724118
- Co-author, “Fragile X Mental Retardation Protein Bidirectionally Controls Dendritic Ih in a Cell Type-Specific Manner between Mouse Hippocampus and Prefrontal Cortex,” Journal of Neuroscience 2020 40(27):5327-5340
- First author, “Functional Access to Neuron Subclasses in Rodent and Primate," Cell Reports 2019 26(10):2818-2832
- Co-author, “Calcium imaging with genetically encoded indicators in behaving primates,” Elife 2016 5:e16178
- Co-author, “Sensitive Cu2+ − Cu2+ distance measurements in a protein-DNA complex by double-quantum coherence ESR,” Journal of Physical Chemistry B 2013 117(20):6227-6230.
- First-author, “Ribosome purification approaches for studying interactions of regulatory proteins and RNAs with the ribosome,” Methods in Molecular Biology 2012; 905:273-89.
- Co-author “ESR spectroscopy identifies inhibitory Cu2+ sites in a DNA-modifying enzyme to reveal determinants of catalytic specificity,” Proceedings of the National Academy of Sciences 2012 Apr 24; 109(17):E993-1000
- Co-author, “The highly conserved KEOPS/EKC complex is essential for a universal tRNA modification, t6A,” EMBO Journal 2011 Mar 2; 30(5):873-81
- First author, “Non-stop mRNA decay initiates at the ribosome,” Molecular Microbiology 2010 Dec 78(5):1159-70.
- Co-author, “A trimeric DNA polymerase complex increases the native replication processivity,” Nucleic Acids Research 2009
- Co-author, “HNHDb: A database on pattern based classification of HNH domains reveals functional relevance of sequence patterns and domain associations,” Bioinformation 2009 4(2): 80-83
- Co-author, “Identification of prophages in bacterial genomes by dinucleotide relative abundance difference,” PLOS ONE 2007 2(11):e1193
- First author, “RNase R degrades non-stop mRNAs selectively in an SmpB-tmRNA-dependent manner,” Molecular Microbiology 2006 62(6):1700-1712
- First author, “tmRNA determinants required for facilitating nonstop mRNA decay,” RNA 2006 12(12):2187-2198
- Co-author, “Database and Comparative Identification of Prophages (book chapter),” Lecture Notes in Control and Information Sciences 2006 344:863-868
- First author, “Analysis of the lambdoid prophage element e14 in the E. coli K-12 genome,” BMC Microbiology 2004 4:4
- First author, “HNH family sub-classification leads to identification of commonality in the His-Me endonuclease superfamily,” Protein Science 2004 13(1):295-300
Membership and activities
- Association of University Technology Managers (AUTM)